[4-amino-2-(4-chlorophenylamino)thiazol-5-yl]-(3-benzyloxyphenyl)methanone | 353512-29-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [4-amino-2-(4-chlorophenylamino)thiazol-5-yl]-(3-benzyloxyphenyl)methanone
• 英文别名: [4-Amino-2-(4-chloroanilino)-1,3-thiazol-5-yl]-(3-phenylmethoxyphenyl)methanone
• CAS: 353512-29-5
• 化学式: C₂₃H₁₈ClN₃O₂S
• 分子量: 435.934
• InChiKey: LKBMCCDTJAZVIE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  106
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
  申请人：——

  公开号：US20040186159A1

  公开（公告）日：2004-09-23

  The use of inhibitors of GSK-3 useful for treating glaucoma is disclosed.

  抑制GSK-3用于治疗青光眼的方法被揭示。
• Use of 2,4-diaminothiazole derivatives
  申请人：——

  公开号：US20010039275A1

  公开（公告）日：2001-11-08

  2,4-Diaminothiazole derivatives which inhibit GSK-3 (glycogen synthase kinase-3) and which are useful for the treatment and/or prevention disorders and diseases wherein an inhibition of GSK-3 is beneficial, especially especially Alzheimer's disease, bipolar disorder, IGT (impaired glucose tolerance), Type 1 diabetes, Type 2 diabetes and obesity.

  抑制GSK-3（糖原合成激酶-3）的2,4-二氨基噻唑衍生物，对治疗和/或预防GSK-3抑制有益的疾病和疾病特别有效，尤其是阿尔茨海默病、双相情感障碍、糖耐量受损（IGT）、1型糖尿病、2型糖尿病和肥胖症。
• [EN] 2,4-DIAMINOTHIAZOLE DERIVATIVES AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 (GSK-3) INHIBITORS<br/>[FR] DERIVES DE 2,4-DIAMINOTHIAZOLE
  申请人：NOVO NORDISK AS

  公开号：WO2001056567A1

  公开（公告）日：2001-08-09

  2,4-Diaminothiazole derivatives which inhibit GSK-3 (glycogen synthase kinase-3) and which are useful for the treatment and/or prevention disorders and diseases wherein an inhibition of GSK-3 is beneficial, especially especially Alzheimer's disease, bipolar disorder, IGT (impaired glucose tolerance), Type 1 diabetes, Type 2 diabetes and obesity.

  2,4-二氨基噻唑衍生物抑制GSK-3（糖原合成酶激酶-3），对于治疗和/或预防抑制GSK-3有益的疾病和疾病特别是阿尔茨海默病、双相情感障碍、IGT（糖耐量受损）、1型糖尿病、2型糖尿病和肥胖症具有用处。
• Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucomatous optic neuropathy
  申请人：Alcon, Inc.

  公开号：EP2281560A1

  公开（公告）日：2011-02-09

  The use of inhibitors of GSK-3 useful for treating, preventing or inhibiting glaucoma, including treating glaucomatous optic neuropathy, is disclosed.

  本研究公开了用于治疗、预防或抑制青光眼（包括治疗青光眼性视神经病变）的 GSK-3 抑制剂的用途。
• INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA
  申请人：Alcon, Inc.

  公开号：EP1430120A1

  公开（公告）日：2004-06-23